证券代码：002338 证券简称：奥普光电 长春奥普光电技术股份有限公司 投资者关系活动记录表 编号：2018-06-001 | --- | --- | |----------------|------------------------------------------------------| | | | | 投资者关系活动 | √ 特定对象调研□分析师会议 | | 类别 | □媒体采访□业绩说明会 | | | □ 新闻发布会□路演活动 | | | □ 现场参观 | | | □ 其他（请文字说明其他活动内容） | | 参与单位名称及 | 王 铄 东北证券股份有限公司 新能源汽车分析师 | | 人员姓名 | 沈建锋 上海合撰资产管理有限公司 管理合伙人 | | 时间 | 14：00-15：00 | | 地点 | 公司三楼会客厅 | | 上市公司接待 | 王小东 奥普公司副总经理兼董事会秘书 | | 人员姓名 | 周 健 奥普公司证券事务代表兼证券部经理 | | 投资者关系活动 | 公司副总经理兼董事会秘书王小东等在公司三楼会客厅 | | 主要内容介绍 | 负责接待了东北证券股份有限公司新能源汽车分析师王铄 ...

证券代码：002338 证券简称：奥普光电 长春奥普光电技术股份有限公司 投资者关系活动记录表 编号：2022-02-001 | --- | --- | --- | |----------------|-------------------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | 特定对象调研 □分析师会议 | | | 类别 | □媒体采访 | □业绩说明会 | | | □新闻发布会 □路演活动 | | | | 现场参观 | | | | □其他 | | | 参与单位名称及 | 泰康资产 陈弘毅 雷鸣 | 黄若谷 张永兴 | | 人员姓名 | 华西证券 张晨飞 | | | 时间 2022 | 年 2 月 11 日 | | | 地点 | 腾讯会议 | | | 上市公司接待人 | 总经理兼董事会秘书：高劲松 | | | 员姓名 | 财务负责人：徐爱民 总经理助理：沈娟 | | | | 证券事务代表：周健 | | | | 问答环节： | | | | 1. 长春光机所对 ...

证券代码：002338 证券简称：奥普光电 长春奥普光电技术股份有限公司 投资者关系活动记录表 编号：2022-01-001 | --- | --- | --- | --- | --- | |----------------|------------------|----------------------------|----------------------------------------------|--------------------------------------------------------| | 投资者关系活动 | | | 特定对象调研 □分析师会议 | | | 类别 | □媒体采访 | | □业绩说明会 | | | | | □新闻发布会 □路演活动 | | | | | 现场参观 | | | | | | □其他 | | | | | 参与单位名称及 | | | 平安养老 李卿睿 五地投资 | 石康宏 | | 人员姓名 | 华西证券 | | 俞能飞 华西证券 | 张晨飞 | | | 中银资管 | | 陆莎莎 中泰证券 | 方城林 | | 时间 2022 | 年 1 | 月 12 ...

Group 1: Acquisition and Control - The company plans to acquire 40% of Yuhang Optical through cash, resulting in a 51.1% ownership post-acquisition, establishing absolute control [2] - The acquisition aims to enhance the company's market position and operational performance [2] Group 2: Product Development and Collaboration - The company collaborates with universities and civilian companies to develop low-cost space payloads and remote sensing products [2] - The core technology involves advanced resin-based composite materials, with a focus on customized resin formulations to meet diverse application needs [2] Group 3: Competitive Advantages - The company possesses simulation analysis capabilities for product design, allowing for structural improvements and weight reduction [3] - The integration with Changchun Institute of Optics will strengthen business foundations and provide funding support for future innovations [3] Group 4: Market Position and Industry Insights - Yuhang Optical is recognized as the largest domestic encoder manufacturer, leading in technology and production scale [3] - The high-end sensor market is dominated by foreign companies, with domestic products holding less than 10% market share [4] - The company aims to break the existing monopoly in high-end products and promote industry advancement [4] Group 5: Application Scenarios - Optical encoders are preferred in high-precision applications, while magnetic encoders are chosen for environments requiring durability, such as in electric vehicles [4]

证券代码：002338 证券简称：奥普光电 长春奥普光电技术股份有限公司 投资者关系活动记录表 编号：2022-09-001 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-----------------------|--------------------------------------------------------|--------------------------------------------------|-------------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | 投资者关系活动 | | 特定对象调研 □分析师会议 | | | | | | | | | 类别 | □媒体采访 | | □业绩说明会 | | | | | | | | | □新闻发布会 □路演活动 | | | | | | | | | | | 现场参观 □其他 | | | | | | | | | | 参与单位名称及 | 泰康资产：刘宁 段 ...

证券代码：002338 证券简称：奥普光电 长春奥普光电技术股份有限公司 投资者关系活动记录表 编号：2022-09-002 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |--------------------------|---------------------------------|-------|--------|--------------------------------------------------------|-------------|-------|--------|----------------|-------|-------| | 投资者关系活动 类别 \n | □媒体采访 \n 现场参观 \n□其他 | | | 特定对象调研 □分析师会议 \n□新闻发布会 □路演活动 | □业绩说明会 | | | | | | | 参与单位名称及 | | | | 银华基金 杜宇、郭磊、梅思寒 | | | | | | | | 人员姓名 | | | | 中银基金 黄珺、王嘉琦、王伟 | | | | | ...

证券代码：002338 证券简称：奥普光电 长春奥普光电技术股份有限公司 投资者关系活动记录表 编号：2022-11-001 | --- | --- | --- | --- | --- | --- | |----------------------------|---------------------------------|-------------|----------------------------------------------------------------|---------------|--------------------------------------------------------| | 投资者关系活动 \n类别 \n | \n□媒体采访 \n 现场参观 \n□其他 | | 特定对象调研 □分析师会议 \n□业绩说明会 \n□新闻发布会 □路演活动 | | | | 参与单位名称及 | 华西证券 | 陆洲 | 林熹 田旺 | 银华基金 郭磊 | | | 人员姓名 | | | 平安养老 蓝逸翔 陈晓光 嘉实基金 | | 吴剑樑 | | | 交银施罗德基金 | | 梁简泓 ...

Financial Performance - The company's revenue for Q3 2022 was ¥138,970,783.02, representing a 45.12% increase compared to the same period last year[7]. - Net profit attributable to shareholders for Q3 2022 was ¥32,975,719.99, an increase of 86.41% year-on-year[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥31,402,667.98, up 86.21% year-on-year[7]. - Basic and diluted earnings per share for Q3 2022 were both ¥0.14, a 100% increase compared to the same period last year[7]. - The net profit for the current period is 76,046,307.81, compared to 49,958,913.78 in the previous period, representing a growth of approximately 52.5%[30]. - The operating profit increased to 78,567,098.83 from 52,865,655.87, marking a rise of about 48.8%[30]. - Basic and diluted earnings per share both stand at 0.29, up from 0.19 in the previous period, indicating a 52.6% increase[32]. - The company’s total profit for the current period is 79,037,800.28, an increase from 52,662,829.07 in the previous period, representing a growth of approximately 49.9%[30]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,876,393,210.51, a 56.86% increase from the beginning of the year[7]. - The company's total assets increased to CNY 1,876,393,210.51 from CNY 1,196,242,303.12 year-over-year[26]. - The total liabilities rose to CNY 660,297,522.63, up from CNY 146,287,837.81 in the previous year[26]. - The equity attributable to shareholders increased to CNY 1,022,387,433.51 from CNY 962,520,820.74 year-over-year[26]. - The company's total equity attributable to shareholders was ¥1,022,387,433.51, a 6.22% increase from the end of the previous year[7]. Cash Flow - The net cash flow from operating activities for the year-to-date was -¥51,911,189.62, a 15.33% improvement compared to the previous year[7]. - Cash flow from operating activities shows a net outflow of -51,911,189.62, an improvement from -61,313,303.61 in the previous period[32]. - The cash and cash equivalents decreased to CNY 54,921,119.04 from CNY 136,359,612.48[20]. - The cash and cash equivalents at the end of the period amount to 54,921,119.04, down from 65,290,644.47 in the previous period[35]. - The company reported a net cash outflow from investing activities of -153,937,428.08, compared to -8,800,949.05 in the previous period[35]. Operational Metrics - Total revenue for the third quarter was CNY 388,682,280.83, a slight decrease from CNY 390,059,005.95 in the previous year[27]. - Total operating costs decreased to CNY 368,394,436.34 from CNY 372,659,745.39 year-over-year[27]. - Research and development expenses were CNY 33,558,760.07, compared to CNY 33,931,455.96 in the same period last year[27]. - Accounts receivable increased significantly to CNY 394,315,658.61 from CNY 184,263,493.22[20]. - Inventory levels rose to CNY 397,961,238.52, compared to CNY 332,702,754.55 in the previous year[20]. - The company incurred credit impairment losses of -5,354,600.63, compared to -3,762,462.95 in the previous period[30]. Non-Recurring Items - Non-recurring gains and losses for the reporting period totaled ¥1,573,052.01, with government subsidies contributing ¥2,756,549.21[8].

Financial Performance - The company's operating revenue for the first half of 2022 was ¥249,711,497.81, a decrease of 15.15% compared to ¥294,296,723.12 in the same period last year[28]. - Net profit attributable to shareholders was ¥36,490,892.78, an increase of 25.67% from ¥29,037,610.81 year-on-year[28]. - The net profit after deducting non-recurring gains and losses was ¥32,935,117.81, reflecting a growth of 22.62% compared to ¥26,858,499.21 in the previous year[28]. - The basic earnings per share increased to ¥0.15, up 25.00% from ¥0.12 in the same period last year[28]. - The total assets at the end of the reporting period were ¥1,266,319,457.62, representing a growth of 5.86% from ¥1,196,242,303.12 at the end of the previous year[28]. - The net assets attributable to shareholders increased to ¥989,411,713.52, a rise of 2.79% from ¥962,520,820.74 at the end of the previous year[28]. - The net cash flow from operating activities was -¥68,077,730.81, a decline of 19.71% compared to -¥56,869,259.96 in the same period last year[28]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion CNY for the first half of 2022, representing a 15% year-over-year growth[48]. - The company reported a gross margin of 45%, indicating strong operational efficiency[48]. - The company reported a total revenue of 591.82 million for the period ending February 28, 2022, with a focus on disinfectants and antibacterial agents[58]. Research and Development - Research and development expenses decreased by 30.60% to ¥17,625,768.89 from ¥25,397,752.80 due to the impact of the pandemic on R&D projects[66]. - The company is investing in R&D for innovative cleaning solutions, with a budget allocation of 50 million CNY for 2022[48]. - The company is investing in R&D for new antibacterial agents, with a budget allocation of $2 million for 2022[54]. - The company is focusing on R&D for new medical devices, including a wearable health monitoring system[61]. - The company has a strong pipeline of innovative technologies, including a flexible stress isolation method for precision optical systems[61]. Market Strategy and Expansion - The company plans to enhance its supply chain management to reduce costs by 10% over the next fiscal year[48]. - Market expansion plans include entering Southeast Asian markets, targeting a 5% market share within the next two years[48]. - The company is exploring potential acquisitions to enhance its product portfolio, with a focus on companies specializing in medical devices[48]. - A new marketing strategy has been implemented, aiming to increase brand awareness by 30% through digital channels[48]. - The company is exploring potential mergers and acquisitions to strengthen its market position and expand its product portfolio[60]. Corporate Governance and Compliance - The company plans not to distribute cash dividends or issue bonus shares[6]. - The company has implemented a talent retention policy to address the risk of talent loss, including training and special incentives[84]. - The company has established an emergency response plan for environmental pollution incidents and conducts regular drills[95]. - The company has completed the approval of its second round of clean production audit reports, aligning with national energy-saving and emission reduction requirements[101]. - The company has strictly fulfilled its commitments regarding avoiding competition with related parties[105]. Shareholder Information - The total number of shares is 240,000,000, with 99.99% being unrestricted shares (239,994,000) and only 0.01% being restricted shares (6,000)[141]. - The largest shareholder is the Chinese Academy of Sciences, holding 42.40% of the shares (101,754,784)[142]. - The total number of shareholders at the end of the reporting period is 27,023[142]. - There were no changes in the holdings of directors, supervisors, and senior management during the reporting period[153]. - The company has not conducted any repurchase transactions during the reporting period[152]. Operational Challenges - The cost of goods sold was ¥171,475,226.04, reflecting a decrease of 15.29% from ¥202,427,090.43 year-on-year[66]. - The company reported a net cash outflow from operating activities of CNY -68,077,730.81 for the first half of 2022, compared to CNY -56,869,259.96 in the first half of 2021[190]. - The total cash outflow from operating activities was 155,964,893.87, a decrease of 27.2% compared to 214,547,196.28 in the same period last year[193]. - The total cash and cash equivalents decreased by 63,252,508.95 during the period, compared to a decrease of 35,368,841.20 in the prior year[195]. - The company distributed dividends totaling 9,600,000.00 during the period, indicating a commitment to shareholder returns despite the financial challenges[199].

Financial Performance - The company's operating revenue for Q1 2022 was ¥115,999,886.79, a decrease of 18.94% compared to ¥143,104,677.95 in the same period last year[3] - Net profit attributable to shareholders was ¥17,152,070.98, representing an increase of 7.41% from ¥15,969,329.32 year-on-year[3] - The total operating revenue for the first quarter of 2022 was CNY 115,999,886.79, a decrease of 19.0% compared to CNY 143,104,677.95 in the same period last year[13] - The net profit for the first quarter was CNY 17,472,969.70, an increase of 4.6% from CNY 16,711,676.16 year-over-year[14] - The total comprehensive income for Q1 2022 was ¥17,472,969.70, compared to ¥16,711,676.16 in Q1 2021, indicating an increase of about 4.6%[15] Assets and Equity - Total assets at the end of the reporting period were ¥1,210,726,534.20, reflecting a 1.21% increase from ¥1,196,242,303.12 at the end of the previous year[3] - The equity attributable to shareholders increased by 1.78%, reaching ¥979,672,891.72 compared to ¥962,520,820.74 at the end of the previous year[3] - The company's total assets increased to CNY 1,210,726,534.20, up from CNY 1,196,242,303.12, representing a growth of 1.2%[13] - Non-current assets totaled CNY 406,894,926.19, compared to CNY 390,022,336.11, indicating an increase of 4.3%[13] - The equity attributable to shareholders of the parent company rose to CNY 979,672,891.72, up from CNY 962,520,820.74, reflecting a growth of 1.8%[13] Cash Flow - The net cash flow from operating activities decreased by 63.34%, amounting to -¥26,406,165.49, primarily due to reduced sales collections impacted by the COVID-19 pandemic[5] - Cash inflows from operating activities totaled ¥96,774,142.26, down from ¥146,484,472.16 in the previous year, reflecting a decrease of approximately 34%[18] - Cash outflows from operating activities were ¥123,180,307.75, compared to ¥162,651,126.35 in the same period last year, showing a reduction of about 24.3%[18] - The net cash flow from operating activities for Q1 2022 was -¥26,406,165.49, worsening from -¥16,166,654.19 in Q1 2021[18] - The cash flow from investing activities showed a net outflow of -¥10,382,492.50, compared to -¥3,665,189.19 in the previous year, indicating a significant increase in investment expenditures[19] - The cash and cash equivalents at the end of Q1 2022 were ¥99,570,954.49, down from ¥126,719,543.49 at the end of Q1 2021, a decrease of approximately 21.4%[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 27,955[6] - The largest shareholder, the Chinese Academy of Sciences, holds 42.40% of the shares, totaling 101,754,784 shares[6] Other Information - The company reported a basic earnings per share of ¥0.07, unchanged from the same period last year[3] - The weighted average return on net assets remained stable at 1.77%[3] - The company received government subsidies amounting to ¥1,769,775.04 during the reporting period[4] - Research and development expenses were CNY 9,002,901.97, down from CNY 12,022,251.68, a decrease of 25.0%[14] - The company reported investment income of CNY 12,486,970.00, significantly higher than CNY 6,439,421.34 in the previous year, marking an increase of 94.5%[14] - The deferred income tax liabilities stood at CNY 2,189,721.42, unchanged from the previous period, indicating stability in this area[13] - The basic and diluted earnings per share remained stable at ¥0.07 for both Q1 2022 and Q1 2021[15] - The company did not conduct an audit for the Q1 2022 report[20] - The report was released on April 28, 2022, by the board of directors of Changchun Optoelectronics Technology Co., Ltd.[21]